Motavizumab Advisory Committee To Consider Possible Study Bias
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerns FDA raised in its "complete response" letter to MedImmune for its monoclonal antibody Rezield (motavizumab) have not been addressed to the agency's complete satisfaction.
You may also be interested in...
Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune
If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)
Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune
If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)
Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?
AstraZeneca subsidiary MedImmune received a "complete response" letter from FDA for its RSV drug motavizumab that did not request additional clinical data, but after an unfavorable advisory committee a year and a half later, the company is looking at the prospect of having to do another trial anyway